Evaluation of Potential Drug-Drug Interactions in Hypercholesterolemia Patients at Teaching Hospital Surabaya

Faizah, Ana Khusnul; Nurrahman, Nani Wijayanti Dyah

doi:10.2991/ahsr.k.210115.064

Cited by 3 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Discrepancies in the prevalence of pDDI may be attributed to differences in study population, study design, and DDI screening instruments ( 24 ). Recent studies conducted in patients with hypercholesterolemia showed that at least one pDDI was detected in 45% and 83.3% of patients, respectively ( 9 , 10 ), which is less compared with the results of our study in which the same was detected in 98.1% of subjects. Our results are in agreement with the studies conducted in Jordan, where the prevalence of pDDI was more than 90% ( 23 , 25 ), which is probably due to the high prevalence of polypharmacy among the respondents, which was also the case here, where 86.1% of the respondents were taking 5 or more medications.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Lalatovic

Pantović

Nedović-Vuković³

et al. 2023

ijph

View full text Add to dashboard Cite

Background: Patients with dyslipidemia are usually multimorbid and require polypharmacy. Therefore, it is important to identify potential drug-drug interactions (pDDIs) in time to prevent their consequences. We aimed to identify and analyze risk factors contributing to their occurrence to guide health professionals. Methods: A prospective cross-sectional study of 216 outpatients with dyslipidemia was conducted from May 2021 to April 2022 in Podgorica, the capital of Montenegro. pDDIs were identified using Medscape, Epocra- tes, and Drugs online interaction checkers. Multivariate regression analysis was performed to evaluate the po- tential predictors of interactions. Results: pDDIs were detected in 212 (98.1%) participants, whereas pDDIs with high clinical significance were detected in 25.46%, 40.74%, and 58.8% of subjects by Drugs, Epocrates, and Medscape, respectively. Polypharmacy emerged as a risk factor for the occurrence of pDDIs in all three checkers in each category of clinical significance. The use of non-steroidal anti-inflammatory drugs and antiplatelet drugs contributes to the incidence of severe pDDIs B=1.014, 95%CI 0.681-1.346, P=0.000 and B=0.492, 95%CI 0.286-0.698, P=0.000, by Epocrates and Medscape respectively. The number of prescribers per patient was a protective factor against moderate pDDI B= -0.858, 95%CI -1.572-(-0.144), P=0.019 and B= -0.956, 95%CI -1.671-(- 0.241), P=0.009, by Medscape and Epocrates, respectively, but a risk factor for the occurrence of minor pDDIs B=0.373, 95%CI 0.033-0.712 P=0.032 and B=0.143, 95%CI 0.042-0.244, P=0.006, by the same checkers. Conclusion: Knowledge of the risk factors contributing to the occurrence of pDDIs is important for the development and implementation of strategies for their prevention, and given the high prevalence of dyslipidemia, understanding these factors seems crucial nowadays.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…The prevalence of pDDIs in patients with dyslipidemia varies from 40% to 80% ( 9 , 10 ), whereas the prevalence of clinically significant pDDIs is 17.43% ( 11 ). However, the risk factors associated with the occurrence of pDDIs in patients with dyslipidemias have been only partially studied.…”

Section: Introductionmentioning

confidence: 99%

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Lalatovic

Pantović

Nedović-Vuković³

et al. 2023

ijph

View full text Add to dashboard Cite

show abstract

“…Interaksi obat adalah kejadian interaksi obat yang dapat terjadi karena penggunaan dengan 2 macam obat bersamaan atau lebih (Baxter, 2010). Interaksi obat merupakan Drug Related Problems (DRP) yang bisa mempengaruhi respon tubuh terhadap obat (Mahamudu et al, 2017;Faizah & Nurrahman, 2020). Interaksi obat dapat terjadi pada pasien yang menerima terapi antihipertensi dan Obat Antiinflamasi Non Steroid (OAINS).…”

Section: Pendahuluanunclassified

Kajian efek interaksi antihipertensi dengan obat antiinflamasi nonsteroid (OAINS) terhadap tekanan darah pada pasien hipertensi

Ayubi,

Faizah,

Yusan

2024

SJP

View full text Add to dashboard Cite

Hypertension causes atherosclerosis which can cause occlusion resulting in subchondral ischemia, which causes the exchange of nutrients and gases into the articular cartilage, which is disrupted and becomes the potential initiator of degradative changes or the so-called osteoarthritis. This review aims to evaluate the effect of antihypertensive drug interactions with NSAIDs on blood pressure. This article review was conducted using a narrative review study. The inclusion criteria in this article are the pharmacodynamic interaction of antihypertensives with NSAIDs in hypertensive patients with osteoarthritis. The results obtained seven articles that meet the inclusion criteria. Hypertensive patients with osteoarthritis receive medications that must be monitored because a drug-drug interaction can decrease the effectiveness of antihypertensives. One of the most widely used drugs in antihypertensive therapy is ACEi, but NSAIDs inhibit the antihypertensive effect on prostaglandin synthesis resulting from bradykinin production. The decrease in blood pressure stimulated by bradykinin plays an essential role in vasodilatation. The interaction of ACEi and NSAIDs can cause an increase in blood pressure with a minimum expansion of 1.1 mmHg. Still, when administering NSAIDs with CCBs, a decrease in blood pressure of 2.86 mmHg is obtained because the action is not dependent on prostaglandins. Based on the results, there were pharmacodynamic changes for both antihypertensive drugs and NSAIDs due to drug interactions that affected the patient's clinical outcome in the form of blood pressure.

show abstract

“…Namun, pemberian multipel terapi dapat menimbulkan adanya interaksi obat yang umumnya merugikan pasien dan sangat perlu dihindari (Yuspita et al, 2021). Apoteker berperan dalam identifikasi dan meminimalkan efek interaksi obat yang dialami pasien (Faizah, 2021). Interaksi obat pada terapi skizofrenia dapat menimbulkan aritmia jantung yang menghambat sistem kardiovaskular, gangguan sistem metabolik (diabetes dan dislipidemia), gangguan sistem saraf pusat seperti parkinson dan tardive dystoni (Puspitasari & Angeline, 2019;Guo et al, 2012).…”

Section: Pendahuluanunclassified

Potensi interaksi obat pada pasien skizofrenia di Rumah Sakit Jiwa Mutiara Sukma tahun 2020

Utami

Darajati²,

Puspitasari³

2022

SJP

View full text Add to dashboard Cite

Schizophrenia is a chronic mental disorder characterized by distortions in thinking and behavior. Schizophrenic patients receive antipsychotic therapy (main) and non-antipsychotic (supportive) for a long time. Prescription drugs are given either single or in combination, that can possible for drug interactions. This study objective to determine the potential drug-drug interactions in schizophrenic patients. The design of this study was cross-sectional with purposive sampling technique. The data used is secondary data from the medical records of inpatient schizophrenia patients at the Mutiara Sukma Mental Hospital NTB in 2020 with a retrospective method. The sample data obtained were 109 medical records. The results showed that there were 82,2% of drug interaction cases, namely the combination of risperodone and lorazepam. The number of major interaction cases is 24,2%, moderate is 72,1% and minor is 3,6%. The high incidence of drug interactions in schizophrenic patients requires closely monitored.

show abstract

Evaluation of Potential Drug-Drug Interactions in Hypercholesterolemia Patients at Teaching Hospital Surabaya

Cited by 3 publications

References 3 publications

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia

Kajian efek interaksi antihipertensi dengan obat antiinflamasi nonsteroid (OAINS) terhadap tekanan darah pada pasien hipertensi

Potensi interaksi obat pada pasien skizofrenia di Rumah Sakit Jiwa Mutiara Sukma tahun 2020

Contact Info

Product

Resources

About